Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PhRMA Promotes Cluster Concept In Japan Reform Wish List

Holistic Changes Needed, US Group Says

Executive Summary

US industry association promotes an exchanges with Japan on bioclusters, while continuing to push for holistic debate on reforms to the country’s national healthcare system and changes to reimbursement pricing it sees as supporting innovation.

You may also be interested in...



APAC As A Clinical Trials Powerhouse

In the last 10 years, the Asia Pacific region has become a hotspot for clinical trials, contributing almost 50% of new clinical trial activity globally in 2021, a new infographic analysis by Citeline's Trialtrove shows.

Chordia Looks To Forge Own Path In Oncology

Chordia only came into being in late 2017 but has already struck its first major licensing-out deal with a major pharma firm. It is now looking ahead to taking forward a portfolio of novel oncology assets originally acquired from investor Takeda.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: a preview of the CTAD Alzheimer’s meeting; US myeloma drug withdrawal puts pressure on GSK; UniQure/CSL's gene therapy sets new US price record; new leadership at Teva; and Merck’s Frazier cautions against profit maximization.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS147251

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel